Atherosclerosis remains a leading disease posing significant threats to human health and life. Oxidative stress plays a critical role in the initiation of early atherosclerosis. Ginsenoside Rb3 has been shown to exert potential therapeutic effects against atherosclerosis due to its antioxidant properties. However, its clinical utility remains constrained to the nanometer scale, offering insufficient targeting capability for atherosclerosis treatment. To address this limitation, we designed a novel Rb3-loaded microbubble system Rb3NPs@MBs.
